000			03281nam a22003975i 4500
001			298072
003			MX-SnUAN
005			20160429155446.0
007			cr nn 008mamaa
008			150903s2010 gw | o |||| 0|eng d
020			_a9783540782810 _99783540782810
024	7		_a10.1007/9783540782810 _2doi
035			_avtls000351603
039		9	_a201509030449 _bVLOAD _c201405060253 _dVLOAD _y201402171141 _zstaff
040			_aMX-SnUAN _bspa _cMX-SnUAN _erda
050		4	_aRC254-282
100	1		_aLiersch, Rüdiger. _eeditor. _9334184
245	1	0	_aAngiogenesis Inhibition / _cedited by Rüdiger Liersch, Wolfgang E. Berdel, Torsten Kessler.
264		1	_aBerlin, Heidelberg : _bSpringer Berlin Heidelberg, _c2010.
300			_axvii, 231 páginas 50 ilustraciones, 25 ilustraciones en color. _brecurso en línea.
336			_atexto _btxt _2rdacontent
337			_acomputadora _bc _2rdamedia
338			_arecurso en línea _bcr _2rdacarrier
347			_aarchivo de texto _bPDF _2rda
490	0		_aRecent Results in Cancer Research, _x0080-0015 ; _v180
500			_aSpringer eBooks
505	0		_aAngiopoietins -- HIF-1? and Cancer Therapy -- Chemokines -- Angiogenesis Inhibition in Cancer Therapy -- Vascular Integrins: Therapeutic and Imaging Targets of Tumor Angiogenesis -- PDGF and Vessel Maturation -- Lymphangiogenesis in Cancer: Current Perspectives -- Compounds in Clinical Phase III and Beyond -- Metronomic Chemotherapy: Principles and Lessons Learned from Applications in the Treatment of Metastatic Prostate Cancer -- Targeting Inflammatory Cells to Improve Anti-VEGF Therapies in Oncology -- Antibody-Based Vascular Tumor Targeting -- Caveolae and Cancer.
520			_aAngiogenesis is attracting increased scientific and clinical interest. The identification of novel mediators and targeting molecules has led to significant progress in our understanding of tumor angiogenesis and tumor vessel targeting. Important advances in cancer treatment have already emerged, and in the future, blood vessel targeting will play a significant role within individualized therapeutic strategies. This volume provides a general overview of the latest developments in angiogenesis inhibition in cancer. All aspects from the bench to the bedside are considered, with detailed attention both to basic research and to its translation into clinical practice. Individual chapters are devoted to the roles of angiopoietins, HIF-1a, chemokines, PDGF and VEGF, and vascular integrins. The latest results of clinical trials on therapeutic compounds are presented, and various advanced targeting strategies are discussed. This book will be invaluable to all who wish to learn of the most recent advances in research and treatment in this exciting field.
590			_aPara consulta fuera de la UANL se requiere clave de acceso remoto.
700	1		_aBerdel, Wolfgang E. _eeditor. _9334185
700	1		_aKessler, Torsten. _eeditor. _9334186
710	2		_aSpringerLink (Servicio en línea) _9299170
776	0	8	_iEdición impresa: _z9783540782803
856	4	0	_uhttp://remoto.dgb.uanl.mx/login?url=http://dx.doi.org/10.1007/978-3-540-78281-0 _zConectar a Springer E-Books (Para consulta externa se requiere previa autentificación en Biblioteca Digital UANL)
942			_c14
999			_c298072 _d298072